Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
ascopubs.org

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study Participants had ...
ascopubs.org

Results of a phase 1/2 study of MHB036C: A potential best-in-class TROP2 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in locally advanced ...

Hemay181: A novel SDC (sugar linked drug conjugate) for solid tumors targeting tumor microenvironment. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...
Inside Higher Ed

Teaching Tip: Using Case Studies in Class

A May 2024 Student Voice survey by Inside Higher Ed and Generation Lab found two in five students believe encouraging faculty to better help connect learning outcomes to issues outside the classroom ...
Business Wire

Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of ...

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ALLEVIATE-2 Phase 3 pivotal clinical ...
Live Science

Ozempic-style drugs treat type 1 diabetes, not only type 2, study finds

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with type 1 diabetes. Semaglutide, the active ingredient in Ozempic, and other ...